Key takeaways
- AHK is Ala-His-Lys and GHK is Gly-His-Lys: one amino acid differs, and the AHK peptide is 14 g/mol heavier.
- GHK-Cu’s cosmetic ingredient name is copper tripeptide-1; we could not confirm an official cosmetic ingredient name for AHK-Cu.
- PubMed lists one record naming AHK-Cu, a 2007 laboratory study of human hair follicles; GHK-Cu has small human skin studies, mostly conference reports.
- A 2026 evidence-map review says AHK-Cu “rests on a thin, poorly characterized evidence base”, and that GHK-Cu’s clinical evidence “remains sparse”.
- FDA’s compounding page lists injectable GHK-Cu, and Australia’s TGA names GHK-Cu among unapproved peptide products; neither mentions AHK-Cu.
01AHK-Cu vs GHK-Cu in one table
The same questions for both, dated 18 November 2026.
| Question | AHK-Cu | GHK-Cu |
|---|---|---|
| What it is | Copper(II) complex of the tripeptide L-alanyl-L-histidyl-L-lysine (Ala-His-Lys) | Copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine (Gly-His-Lys) |
| The difference | Alanine in first position | Glycine in first position |
| Peptide mass, without copper | 354.41 g/mol | 340.38 g/mol |
| Cosmetic ingredient (INCI) name | Not confirmed at an official source | Copper tripeptide-1; also prezatide copper, GHK copper |
| Origin | Synthetic | GHK was isolated from human plasma in 1973 |
| PubMed records naming it in the title or abstract (18 Nov 2026) | 1 | More than 100, depending on the names searched |
| Laboratory and animal evidence | One study (2007): human hair follicles kept alive outside the body, and cultured cells (T4) | Many cell and animal studies (T4, T3) |
| Human studies | None published that we found. One registered study includes it in a multi-peptide skin serum with GHK-Cu; no results | Small, short skin studies, mostly conference reports; one PubMed-indexed randomised trial of a skin-care regimen, with 13 completers, found no objective difference. Four registered skin studies, three with other active ingredients, none with posted results |
| Independent review (2026) | “Shares the motif but rests on a thin, poorly characterized evidence base” | Clinical evidence “remains sparse and does not meet contemporary active-entity quality standards” |
| US cosmetic safety review | Not named in the 2018 CIR review summary | CIR, an industry-funded panel, 2018: no safety concern at the low concentrations used in cosmetics |
| FDA compounding page | Not listed | Listed for injectable routes among withdrawn Category 2 nominations, citing possible immune reactions |
| Australia (TGA, Apr 2026) | Not named in the unapproved-peptides advisory | Named among examples of unapproved peptide products, “often supplied in injectable form” |
| WADA | Not named on the 2026 or 2027 List; check with your anti-doping body | Not named on the 2026 or 2027 List; check with your anti-doping body |
02Are AHK-Cu and GHK-Cu the same molecule?
No. Both are three amino acids bound to copper, and two of the three are the same: histidine and lysine. The first differs: AHK-Cu has alanine where GHK-Cu has glycine. That makes the AHK peptide 354.41 g/mol against 340.38 g/mol for GHK, a gap of 14 g/mol that a mass spectrometry result can show (mass spectrometry explained).
Both hold copper(II) through histidine. A 2026 review describes GHK-Cu as an endogenous tripeptide binding copper one-to-one through histidine, backbone nitrogens and its amino end, and AHK-Cu as a synthetic peptide with “histidine-anchored” copper binding that “shares the motif”. Why the copper makes GHK-Cu blue: why is GHK-Cu blue?
Names. GHK-Cu’s cosmetic ingredient (INCI) name is copper tripeptide-1, and prezatide copper is another name for it. For AHK-Cu we could not confirm an official cosmetic ingredient name: PubChem’s record lists none, and the EU’s CosIng inventory did not load for our tools on 18 November 2026. Research on one is not research on the other, so a label or lab report should name the exact peptide.
03How have AHK-Cu and GHK-Cu been studied?
Very unevenly. Cell and laboratory findings are not evidence of an effect in people.
AHK-Cu. PubMed lists one record that names AHK-Cu in its title or abstract (18 November 2026): a 2007 study at Seoul National University that applied it to human hair follicles kept alive outside the body and to cultured dermal papilla cells, and measured follicle elongation, cell growth and markers of cell death (T4). On ClinicalTrials.gov, one registered study names it: an early phase 1, single-group study planned for 48 adults that tests several agents, including a skin serum containing AHK-Cu, GHK-Cu and three other peptides, with untreated skin sites as controls. It is enrolling by invitation, has no results, and cannot separate either copper peptide’s contribution.
GHK-Cu. More than 100 PubMed records name GHK-Cu in the title or abstract: 105 under GHK-Cu, copper tripeptide-1, prezatide and their spelling variants (18 November 2026). Its research is mostly in cells and animals. The human studies applied it to the skin: small, short cosmetic studies, most reported as conference posters and known through a 2018 review by GHK’s discoverer, and one PubMed-indexed randomised trial of a skin-care regimen after laser resurfacing, in which 13 people completed and objective measures found no difference. A 2026 systematic review describes the human literature as “thin and fragmented”, and found that about 35% of the GHK-Cu primary literature it included lists Loren Pickart or Anna Margolina of Skin Biology Inc. as authors. Detail: topical GHK-Cu and the GHK-Cu research guide.
Independent reviewers. A 2026 evidence-map review in Pharmaceutics, whose authors declare no conflicts of interest, compared GHK-Cu with related copper peptides. It wrote that AHK-Cu “shares the motif but rests on a thin, poorly characterized evidence base”, and that GHK-Cu’s clinical evidence “remains sparse and does not meet contemporary active-entity quality standards”. We found no study that compared them (PubMed and ClinicalTrials.gov, 18 November 2026). Hair-specific research on both: copper peptides and hair.
04How do cosmetic and medicines rules treat AHK-Cu and GHK-Cu?
In a cosmetic, either falls under the same product rules. The differences are in what has been reviewed and what regulators have named.
United States. FDA says “cosmetic products and ingredients, with the exception of color additives, do not require FDA approval before they go on the market”, and that whether a product is a cosmetic or a drug “is determined by a product’s intended use”. In 2018 the Cosmetic Ingredient Review panel, which the cosmetics industry’s trade association funds and which describes its process as independent, assessed tripeptide-1 (GHK), its metal salts and related ingredients. It noted that copper tripeptide-1 is used in cosmetic products and wrote that “the low use concentrations and negative safety test data reviewed obviate any concerns relating to the safety of these ingredients in cosmetic products”. Its published summary does not name AHK-Cu. Separately, FDA’s compounding page lists GHK-Cu for injectable routes among substances whose Category 2 nominations were withdrawn, citing possible immune reactions; AHK-Cu does not appear on it (page current 22 April 2026).
EU and Great Britain. Each cosmetic product needs a safety assessment before sale, whichever peptide it contains. We could not read the EU’s CosIng ingredient inventory for either name. In the UK, the MHRA decides whether “the claims that are made or the active substance(s) present” make a borderline product a medicine.
Australia. The TGA’s April 2026 safety advisory names GHK-Cu among examples of unapproved peptide products, “often supplied in injectable form”; it does not name AHK-Cu. We read it on the Internet Archive capture of 10 August 2026, because tga.gov.au did not respond. We have not verified how Australian rules treat a cosmetic containing either. More: peptides in skincare.
Sport. Neither is named on WADA’s 2026 Prohibited List or on the 2027 List, in force from 1 January 2027. Class S0 covers any pharmacological substance not addressed elsewhere “and with no current approval by any governmental regulatory health authority for human therapeutic use”; anti-doping organisations decide how it applies. See peptides and anti-doping.
05What we don’t know about AHK-Cu and GHK-Cu
- Anything about AHK-Cu in people. We found no published human study of it, and the one registered study mixes it with other agents.
- How the two compare. We found no study that tested them side by side.
- AHK-Cu’s official cosmetic ingredient name and EU inventory status, which we could not confirm.
- The long-term safety of either in people, and anything about injected AHK-Cu.
- Which copper peptide a product holds. Only an identity result on that lot’s lab report can show it: how to read a COA.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.